Bausch Health's Salix grants nonexclusive license to Teva Pharmaceuticals, settles suit

Bausch Health subsidiary Salix Pharmaceuticals settled an intellectual property case against Teva Pharmaceuticals over Salix's ulcerative colitis drug Apriso.

What you should know:

1. Salix will give Teva a nonexclusive license to market a generic version of Apriso in the U.S. effective Oct. 1, 2021.

2. Bausch will not make any payments to Teva or provide the drugmaker any "transfers of value."

3. Both parties will dismiss pending litigation related to Apriso.

4. Salix's Apriso patent expires in 2030.

More articles on surgery centers: 
Looser ASC requirements, 24-hour stays & more: 3 regulation updates to know
Becoming an administrator & what separates ASCs from one another — 2 insights from a recruiter
Hospital-owned ASC doesn't get tax exemption, Pennsylvania court says 

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers